Abstract:Abstract Background/Aims Methotextrate is a widely used disease modifying anti-rheumatic drug (DMARD) used to treat connective tissue disorder and inflammatory arthritis. Methotextrate induced neurological toxicity includes vomiting, headaches, blurred vision, mood alteration, somolescence, brain fog, hyperosmia, leukoencephalopathy and pseudo-stroke like syndrome. Here we report a case of methotextrate induced headache with leptomeningeal enhancement, which reversed after stopping the methotextrate. Methods A 66 year old male with known diagnosis of sero-positive rheumatoid arthritis with past medical history of Hodgkins lymphoma in remission. He started on dual DMARD combination of 15 mg methotextrate subcutaneously once a week and 200 mg hydroxychlroquin twice daily. Thereafter he reported history of headaches, which needed hospital admission. He underwent a CT-head scan on admission which did not show any acute concerns. The case was then discussed with the haematology team and later he underwent a PET scan of the whole body which was reviewed in Lymphoma MDT which showed non-specific uptake in hilar nodes, which does not significantly increase the suspicion of lymphoma relapse. On discharge he had MRI head contrast and MRV cerebral veins, which showed a few areas of irregular nodular curvilinear foci of predominantly meningeal enhancement noted in occipital lobes and adjacent T2 /flair hypertense signal noted in relation to these. These changes were discussed in neurology MDT, given the history of lymphomas a possibility, though rare in the absence of systemic relapse. The differential included low dose (oral) methotextrate related neurotoxicity. Patient was advised to stop methotextrate, they repeated MRI scan 3 weeks later which showed disappearance of the curvilinear lesions with leptomeningeal enhancement and patient reported headaches improved. Results List of investigations 1. CSF- profile, no protein, no growth 2. CSF PCR panel for Adeno/Paracheo/Entero/Varicella Zoster/HSV type 1&2-negative 3. Histology report of CSF- No evidence of lymphoma 4. Neuronal Ab: Purkinje cell/ Hu Ab/Ri Ab amd Anti-amphiphysin Ab-negative 5. Myeloma screen- no paraprotein detected 6. Virus panel- EBV- IgM-, HIV /Hep B and C, Cytomegalovirus IgM-not detected. Conclusion Methotextrate is a potent anti-metabolite preventing the formation of tetrahydrofolate, and used as immunosuppressant and anti-neoplastic medication. Though the exact mechanism of the neurotoxicity is not known, the common hypothesis include; interference with myelin synthesis or maintenance and/or interference with neurotransmitter synthesis. The case reported here reiterates the importance of recognizing the neurological side effects in patients on methotextrate even on low dose of methotextrate. It also emphasizes the fact that the neurological changes are reversible on stopping methotextrate. Headaches can still be a side effect and might mimic stroke like episode in patients treated with low dose of subcutaneous methotextrate and hence stopping the medication should be considered in such cases. Disclosure P. Doddamani: None. A. Kinder: None.

Myelopathy following intrathecal methotrexate administration:Review of English literature

Paraplegia resulting from intrathecal methotrexate administration in 11 cases:Review of Chinese literature

Anterior lumbosacral polyradiculoneuropathy following intrathecal methotrexate administration: a case report and literature update

Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate

Intrathecal morphine combined with ropivacaine induces spinal myoclonus in cancer patients with an implanted intrathecal drug delivery system: Three case reports.

Ncmp-05. Clinical And Radiographic Improvement With Replacement Of Folate Metabolites In A Patient With Intrathecal Methotrexate-Induced Myelopathy

A case of myelopathy due to intrathecal chemotherapy and literature review

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

[Efficacy and Security of Intrathecal with Methotrexate in the Treatment of Meningeal Carcinomatosis]

Potential neurotoxicity associated with methotrexate

Clinical research on acute paraplegia resulting from intrathecal chemotherapy

Intrathecal chemotherapy-related myeloencephalopathy in a young child with acute lymphoblastic leukemia

Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites

Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose

Intrathecal methotrexate, central nervous system toxicity, and response to N-methyl-D-aspartate antagonism: An adult case series

Intracranial tumor lysis and cerebral edema after administration of intrathecal methotrexate: a case report and discussion

E032 Low dose methotextrate induced leukoencephalopathy: a case report

Intrathecal dexamethasone and methotrexate treatment of neoplastic meningitis from solid tumors

Disseminating Necrotizing Leukoencephalopathy Associated With Intra-CSF Methotrexate Chemotherapy

Myelopathy Associated with Systemic Lupus Erythematosus: a Clinical Analysis of 10 Cases and Review of Literature

Risk factors for high‐dose methotrexate associated toxicities in patients with primary central nervous system lymphoma